Research
Hormonal
In non-T2DM individuals, retatrutide produced substantial weight loss and improved glucose levels.
Retatrutide may also benefit non-T2DM individuals seeking weight loss and improved glucose control.
StrongSupportsmedium confidence
In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side effects.
Why this rating
Based on phase-2 trial data mentioned in the abstract.
Source
Retatrutide: a triple incretin receptor agonist for obesity management
Avik Ray · Expert Opinion on Investigational Drugs · 2023
DOI 10.1080/13543784.2023.2276754
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Retatrutide exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).Strong
- Retatrutide raises cardiovascular safety concerns due to dose-dependent increases in heart rate and incidents of mild to moderate cardiac arrhythmias.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →